entertainment -WSS

entertainment

author：explore 2025-09-30 12:11:00 - browse：4

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： The pink breast cancer awareness ribbon needs a redesign

WSS

Mike Pence clashes with Tucker Carlson in Iowa

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

WHO may add ‘noma' to its list of neglected tropical diseases

Argenx drug significantly slows progression of nerve disorder

Why police arrested suspected Gilgo Beach killer away from his house

Celiac disease study examines precisely how gluten triggers injury

explore

entertainment

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Georgia court denies Trump's request to quash DA's 2020 election probe

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Argenx drug significantly slows progression of nerve disorder

At least 13 dead in Texas as scorching temps continue

Blood tests recalled over risk of missed heart attack diagnosis

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Duchenne breakthrough therapy leaves behind pioneering families

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

focus

Congress likely to miss an opportunity to fix drug shortages issue

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Involuntary treatment for addiction doesn't work

Woman gored by Bison at Yellowstone

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

knowledge

focus

focus

explore